<DOC>
	<DOCNO>NCT01418937</DOCNO>
	<brief_summary>This phase IIIb study design assess safety GlaxoSmithKline Biological 's HPV vaccine GSK580299 female subject take part HPV-023 ( NCT00518336 ) study receive placebo HPV-001 ( NCT00689741 ) study .</brief_summary>
	<brief_title>Safety Evaluation Human Papillomavirus ( HPV ) Vaccine Healthy Female Control Subjects From GSK HPV 023 Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A subject previously enrol Study HPV023 ( NCT00518336 ) , receive placebo Study HPV001 ( NCT00689741 ) , 26 year age old . Written informed consent must obtain subject prior enrollment . Free obvious health problem establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Pregnant breastfeeding : enrollment defer least three month delivery breastfeeding cease . A woman plan become pregnant , likely become pregnant planning discontinue contraceptive precaution vaccination phase study , two month last vaccine dose . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Previous vaccination HPV plan administration another HPV vaccine study foreseen protocol . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day dose vaccine , exception administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day dose study vaccine . Enrollment defer subject outside specify window . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous administration vaccine component . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Cancer autoimmune disease treatment . History reaction hypersensitivity likely exacerbate component vaccine . History neurological disorder seizure . Acute disease and/or fever time enrollment . Enrollment deferred condition resolve . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , opinion investigator precludes administration study vaccine .</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HPV vaccine</keyword>
	<keyword>serious adverse event ( SAEs )</keyword>
	<keyword>medically significant condition</keyword>
	<keyword>cervical neoplasia</keyword>
</DOC>